Pharmacological treatments for acute respiratory distress syndrome: Systematic review

Minerva Anestesiologica

Volumn 81, Issue 5, 2015, Pages 567-588

  Duggal, A ^a   Ganapathy, A ^b   Ratnapalan, M ^c   Adhikari, N K J ^d,e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b University of Queensland   (Canada)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Adult; Drug therapy; Meta analysis; Respiratory distress syndrome

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; ACETYLCYSTEINE; ACTIVATED PROTEIN C; CISATRACURIUM; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LEUKOCYTE ELASTASE INHIBITOR; METHYLPREDNISOLONE; NITRIC OXIDE; PLACEBO; PREDNISOLONE; PROSTAGLANDIN E1; RUTOSIDE; SALBUTAMOL; SURFACTANT; ATRACURIUM BESILATE; NEUROMUSCULAR BLOCKING AGENT;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; ARTIFICIAL VENTILATION; CARDIOVASCULAR SURGERY; COCHRANE LIBRARY; DATA BASE; DISEASE SEVERITY; EMBASE; HUMAN; LOW DRUG DOSE; MEDLINE; MORTALITY; POPULATION; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTEMATIC REVIEW; THORAX BLUNT TRAUMA; ANALOGS AND DERIVATIVES; META ANALYSIS; RESPIRATORY DISTRESS SYNDROME, ADULT;

ATRACURIUM; HUMANS; NEUROMUSCULAR NONDEPOLARIZING AGENTS; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 84929718889     PISSN: 03759393     EISSN: 18271596     Source Type: Journal    
DOI: None     Document Type: Article

References (82)

1. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342:1334-49.
2. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E et al. Acute respiratory distress syndrome: The berlin definition. JAMA 2012;307:2526-33.
3. Phua J, Badia JR, Adhikari NK, Friedrich JO, Fowler RA, Singh JM et al. Has mortality from acute respiratory distress syndrome decreased over time?: A systematic review. Am J Respir Crit Care Med 2009;179:220-7.
4. Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, Al-Saidi F et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 2003;348:683-93.
5. Herridge MS, Tansey CM, Matte A, Tomlinson G, Diaz-Granados N, Cooper A et al. Functional disability 5 years after acute respiratory distress syndrome. N Engl J Med 2011;364:1293-304.
6. Adhikari N, Burns KE, Meade MO. Pharmacologic treatments for acute respiratory distress syndrome and acute lung injury: Systematic review and meta-analysis. Treat Respir Med 2004;3:307-28.
7. Adhikari N, Burns KE, Meade MO. Pharmacologic therapies for adults with acute lung injury and acute respiratory distress syndrome. Cochrane Database Syst Rev 2004;CD004477.
8. Cracknell J, Muller A, Pederson T. Cochrane anesthesia group module. update software, oxford [Internet]. Available from www.thecochranelibrary.com/ [cited 2015, Jan 8].
9. Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol 2002;31:150-3.
10. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [Internet]. Available from www.cochrane-handbook.org [cited 2015, Jan 8].
11. Bernard GR, Artigas A, Brigham KL, Carlet J, Falke K, Hudson L. Report of the american-european consensus conference on ARDS: Definitions, mechanisms, relevant outcomes and clinical trial coordination. the consensus committee. Intensive Care Med 1994;20:225-32.
12. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med 1992;116:78-84.
13. Afshari A, Brok J, Moller AM, Wetterslev J. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) and acute lung injury in children and adults. Cochrane Database Syst Rev 2010;CD002787.
14. Adhikari NK, Dellinger RP, Lundin S, Payen D, Vallet B, Gerlach H et al. Inhaled nitric oxide does not reduce mortality in patients with acute respiratory distress syndrome regardless of severity: Systematic review and meta-analysis. Crit Care Med 2014;42:404-12.
15. Galvin IM, Steel A, Pinto R, Ferguson ND, Davies MW. Partial liquid ventilation for preventing death and morbidity in adults with acute lung injury and acute respiratory distress syndrome. Cochrane Database Syst Rev 2013;7:CD003707.
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
17. Montori V, Guyatt G, Oxman A, Cook D. Summarizing the evidence: Fixed-effects and random-effects models. In: Guyatt G, Rennie D, eds. Users' Guide to the Medical Literature: A Manual for Evidence-Based Clinical Practice. Chicago: AMA press; 2002:539-46.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
19. Spragg RG, Lewis JF, Walmrath HD, Johannigman J, Bellingan G, Laterre PF et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N Engl J Med 2004;351:884-92.
20. Bernard GR, Wheeler AP, Arons MM, Morris PE, Paz HL, Russell JA et al. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. the antioxidant in ARDS study group. Chest 1997;112:164-72.
21. Ortolani O, Conti A, De Gaudio AR, Masoni M, Novelli G. Protective effects of N-acetylcysteine and rutin on the lipid peroxidation of the lung epithelium during the adult respiratory distress syndrome. Shock 2000;13:14-8.
22. Slotman GJ, Kerstein MD, Bone RC, Silverman H, Maunder R, Hyers TM et al. The effects of prostaglandin E1 on non-pulmonary organ function during clinical acute respiratory failure. the prostaglandin E1 study group. J Trauma 1992;32:480-8; discussion 488-9.
23. Bone RC, Slotman G, Maunder R, Silverman H, Hyers TM, Kerstein MD. Randomized double-blind, multicenter study of prostaglandin E1 in patients with the adult respiratory distress syndrome. prostaglandin E1 study group. Chest 1989;96:114-9.
24. Abraham E, Park YC, Covington P, Conrad SA, Schwartz M. Liposomal prostaglandin E1 in acute respiratory distress syndrome: A placebo-controlled, randomized, double-blind, multicenter clinical trial. Crit Care Med 1996;24:10-5.
25. Abraham E, Baughman R, Fletcher E, Heard S, Lamberti J, Levy H et al. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: A controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS study group. Crit Care Med 1999;27:1478-85.
26. Holcroft JW, Vassar MJ, Weber CJ. Prostaglandin E1 and survival in patients with the adult respiratory distress syndrome. A prospective trial. Ann Surg 1986;203:371-8.
27. Rossignon MD, Khayat D, Royer C, Rouby JJ, Jacquillat C, Viars P. Functional and metabolic activity of polymorphonuclear leukocytes from patients with adult respiratory distress syndrome: Results of a randomized double-blind placebo-controlled study on the activity of prostaglandin E1. Anesthesiology 1990;72:276-81.
28. Shoemaker WC, Appel PL. Effects of prostaglandin E1 in adult respiratory distress syndrome. Surgery 1986;99:275-83.
29. Vincent JL, Brase R, Santman F, Suter PM, McLuckie A, Dhainaut JF et al. A multi-centre, double-blind, placebo-controlled study of liposomal prostaglandin E1 (TLC C-53) in patients with acute respiratory distress syndrome. Intensive Care Med 2001;27:1578-83.
30. Domenighetti G, Suter PM, Schaller MD, Ritz R, Perret C. Treatment with N-acetylcysteine during acute respiratory distress syndrome: A randomized, double-blind, placebo-controlled clinical study. J Crit Care 1997;12:177-82.
31. Jepsen S, Herlevsen P, Knudsen P, Bud MI, Klausen NO. Antioxidant treatment with N-acetylcysteine during adult respiratory distress syndrome: A prospective, randomized, placebo-controlled study. Crit Care Med 1992;20:918-23.
32. Suter PM, Domenighetti G, Schaller MD, Laverriere MC, Ritz R, Perret C. N-acetylcysteine enhances recovery from acute lung injury in man. A randomized, double-blind, placebo-controlled clinical study. Chest 1994;105:190-4.
33. Moradi M, Mojtahedzadeh M, Mandegari A, Soltan-Sharifi MS, Najafi A, Khajavi MR et al. The role of glutathione-S-transferase polymorphisms on clinical outcome of ALI/ARDS patient treated with N-acetylcysteine. Respir Med 2009;103:434-41.
34. Bernard GR, Luce JM, Sprung CL, Rinaldo JE, Tate RM, Sibbald WJ et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 1987;317:1565-70.
35. Laggner AN, Lenz K, Base W, Druml W, Schneeweiss B, Grimm G et al. Effect of high-dose prednisolone on lung fluid in patients with non-cardiogenic lung edema. Wien Klin Wochenschr. 1987;99:245-9.
36. Weigelt JA, Norcross JF, Borman KR, Snyder WH. Early steroid therapy for respiratory failure. Arch Surg 1985;120:536-40.
37. Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, Kelso T. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: A randomized controlled trial. JAMA 1998;280:159-65.
38. Steinberg KP, Hudson LD, Goodman RB, Hough CL, Lanken PN, Hyzy R et al. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006;354:1671-84.
39. Meduri GU, Golden E, Freire AX, Taylor E, Zaman M, Carson SJ et al. Methylprednisolone infusion in early severe ARDS: Results of a randomized controlled trial. Chest 2007;131:954-63.
40. Anzueto A, Baughman RP, Guntupalli KK, Weg JG, Wiedemann HP, Raventos AA et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. exosurf acute respiratory distress syndrome sepsis study group. N Engl J Med 1996;334:1417-21.
41. Gregory TJ, Steinberg KP, Spragg R, Gadek JE, Hyers TM, Longmore WJ et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997;155:1309-15.
42. Kesecioglu J, Beale R, Stewart TE, Findlay GP, Rouby JJ, Holzapfel L et al. Exogenous natural surfactant for treatment of acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med 2009;180:989-94.
43. Perez YB, Albuerne YA, Cadanas ED, Lima OF, Pina RU, Flores CMB. Effects of surfacen in low and maintained dose in the treatment of ARDS. preliminary results. Basic Clin Pharmacol Toxicol 2010;107(Suppl 1):190.
44. Reines HD, Silverman H, Hurst J, Warren J, Williams J, Rotello L. Effects of two concentrations of nebilized surfactant (exosurf) in sepsis-induced adult respiratory distress syndrome (ARDS). Crit Care Med 1992;20(4 Suppl.):S61.
45. Spragg RG, Lewis JF, Wurst W, Hafner D, Baughman RP, Wewers MD et al. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am J Respir Crit Care Med 2003;167:1562-6.
46. Tsangaris I, Galiatsou E, Kostanti E, Nakos G. The effect of exogenous surfactant in patients with lung contusions and acute lung injury. Intensive Care Med 2007;33:851-5.
47. Walmrath D, De Vaal JB, Bruining HA, Kilian JG, Papazian L, Hohlfeld J. Treatment of ARDS with a recombinant SP-C (rSP-C) based synthetic surfactant. Am J Respir Crit Care Med 2000;161:A379.
48. Weg JG, Balk RA, Tharratt RS, Jenkinson SG, Shah JB, Zaccardelli D et al. Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome. JAMA 1994;272:1433-8.
49. Endo S, Sato N, Yaegashi Y, Suzuki Y, Kojika M, Yamada Y et al. Sivelestat sodium hydrate improves septic acute lung injury by reducing alveolar dysfunction. Res Commun Mol Pathol Pharmacol 2006;119:53-65.
50. Gottlieb JE, Elmer M, Steiner R. Efficacy of intravenous ICI 200,880, a neutrophil elastase inhibitor, in the treatment of adult respiratory distress syndrome (ARDS). Chest 1994;106(2 Suppl):67S.
51. Kadoi Y, Hinohara H, Kunimoto F, Saito S, Goto F, Kosaka T et al. Pilot study of the effects of ONO-5046 in patients with acute respiratory distress syndrome. Anesth Analg 2004;99:872-7, table of contents.
52. Ryugo M, Sawa Y, Takano H, Matsumiya G, Iwai S, Ono M et al. Effect of a polymorphonuclear elastase inhibitor (sivelestat sodium) on acute lung injury after cardiopulmonary bypass: Findings of a double-blind randomized study. Surg Today 2006;36:321-6.
53. Tamakuma S, Ogawa M, Aikawa N, Kubota T, Hirasawa H, Ishizaka A et al. Relationship between neutrophil elastase and acute lung injury in humans. Pulm Pharmacol Ther 2004;17:271-9.
54. Zeiher BG, Artigas A, Vincent JL, Dmitrienko A, Jackson K, Thompson BT et al. Neutrophil elastase inhibition in acute lung injury: Results of the STRIVE study. Crit Care Med 2004;32:1695-702.
55. Forel JM, Roch A, Marin V, Michelet P, Demory D, Blache JL et al. Neuromuscular blocking agents decrease inflammatory response in patients presenting with acute respiratory distress syndrome. Crit Care Med 2006;34:2749-57.
56. Gainnier M, Roch A, Forel JM, Thirion X, Arnal JM, Donati S et al. Effect of neuromuscular blocking agents on gas exchange in patients presenting with acute respiratory distress syndrome. Crit Care Med 2004;32:113-9.
57. Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med 2010;363:1107-16.
58. Perkins GD, McAuley DF, Thickett DR, Gao F. The beta-agonist lung injury trial (BALTI): A randomized placebo-controlled clinical trial. Am J Respir Crit Care Med 2006;173:281-7.
59. Smith FG, Perkins GD, Gates S, Young D. Effect of intravenous beta-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): Multicentre, randomized controlled trial. Lancet 2012;379:229-35.
60. Paine R, Standiford TJ, Dechert RE, Moss M, Martin GS, Rosenberg AL et al. A randomized trial of recombinant human granulocyte-macrophage colony stimulating factor for patients with acute lung injury. Crit Care Med 2012;40:90-7.
61. Presneill JJ, Harris T, Stewart AG, Cade JF, Wilson JW. A randomized phase II trial of granulocyte-macrophage colony-stimulating factor therapy in severe sepsis with respiratory dysfunction. Am J Respir Crit Care Med 2002;166:138-43.
62. Morris PE, Papadakos P, Russell JA, Wunderink R, Schuster DP, Truwit JD et al. A double-blind placebo-controlled study to evaluate the safety and efficacy of L-2-oxothiazolidine-4-carboxylic acid in the treatment of patients with acute respiratory distress syndrome. Crit Care Med 2008;36:782-8.
63. Reines HD, Halushka PV, Olanoff LS, Hunt PS. Dazoxiben in human sepsis and adult respiratory distress syndrome. Clin Pharmacol Ther 1985;37:391-5.
64. Tuxen DV, Wilson JW, Cade JF. Prevention of lower respiratory herpes simplex virus infection with acyclovir in patients with the adult respiratory distress syndrome. Am Rev Respir Dis 1987;136:402-5.
65. Steinberg SM, Rodriguez JL, Bitzer LG, Rhee JW, Kelley KA, Flint LM. Indomethacin treatment of human adult respiratory distress syndrome. Circ Shock 1990;30:375-84.
66. Ardizzoia A, Lissoni P, Tancini G, Paolorossi F, Crispino S, Villa S et al. Respiratory distress syndrome in patients with advanced cancer treated with pentoxyfylline: A randomized study. Supportive Care in Cancer 1993;1:331-2, 333.
67. Bernard GR, Wheeler AP, Naum CC, Morris PE, Nelson L, Schein R. A placebo-controlled, randomized trial of IL-10 in acute lung injury (ALI). Chest 1999;116(4 Supp 2):206S.
68. ARDS Network. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: A randomized controlled trial. the ARDS network. JAMA 2000;283:1995-2002.
69. ARDS Network. Randomized, placebo-controlled trial of lisofylline for early treatment of acute lung injury and acute respiratory distress syndrome. Crit Care Med 2002;30:1-6.
70. Liu KD, Levitt J, Zhuo H, Kallet RH, Brady S, Steingrub J et al. Randomized clinical trial of activated protein C for the treatment of acute lung injury. Am J Respir Crit Care Med 2008;178:618-23.
71. Vincent JL, Artigas A, Petersen LC, Meyer C. A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome. Crit Care Med 2009;37:1874-80.
72. Craig TR, Duffy MJ, Shyamsundar M, McDowell C, O'Kane CM, Elborn JS et al. A randomized clinical trial of hydroxymethylglutaryl- coenzyme a reductase inhibition for acute lung injury (the HARP study). Am J Respir Crit Care Med 2011;183:620-6.
73. Chen QH, Zheng RQ, Lin H, Wang HL, Lu NF, Shao J et al. A prospective randomized control clinical study of the effect of xuebijing injection on prognosis of acute respiratory distress syndrome patients. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2009;21:405-8.
74. The ARDS Clinical Trial Network. Randomized, placebo-controlled trial of an aerosolized beta-agonist for treatment of acute lung injury. Am J Respir Crit Care Med 2011;184:561-8.
75. Morris PE, Steingrub JS, Huang BY, Tang S, Liu PM, Rhode PR et al. A phase I study evaluating the pharmacokinetics, safety and tolerability of an antibody-based tissue factor antagonist in subjects with acute lung injury or acute respiratory distress syndrome. BMC Pulm Med 2012;12:5-2466-12-5.
76. Rubenfeld GD. Epidemiology of acute lung injury. Crit Care Med 2003;31(4 Suppl):S276-84.
77. Slutsky AS. Neuromuscular blocking agents in ARDS. N Engl J Med 2010;363:1176-80.
78. Pereira TV, Horwitz RI, Ioannidis JP. Empirical evaluation of very large treatment effects of medical interventions. JAMA 2012;308:1676-84.
79. Alhazzani W, Alshahrani M, Jaeschke R, Forel JM, Papazian L, Sevransky J. Neuromuscular blocking agents in acute respiratory distress syndrome: A systematic review and meta-analysis of randomized controlled trials. Crit Care 2013;17:R43.
80. Lamontagne F, Briel M, Guyatt GH, Cook DJ, Bhatnagar N, Meade M. Corticosteroid therapy for acute lung injury, acute respiratory distress syndrome, and severe pneumonia: A meta-analysis of randomized controlled trials. J Crit Care 2010;25:420-35.
81. Zhang L, Sun J, Xue X, Wang J. Exogenous pulmonary surfactant for acute respiratory distress syndrome in adults: A systematic review and meta-analysis. Experiment Therapeut Med 2013;5:237-42.
82. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988;138:720-3.